Ningkang Ruizhu Secures Tens of Millions of RMB in Financing with Riemann Hypothesis as Exclusive Financial Advisor

Recently, Ningkang Ruizhu Biopharmaceutical (Zhuhai) Co., Ltd. (hereinafter referred to as “Ningkang Ruizhu” or the “Company”) announced that funds including RHC, Zhuhai Technology Venture Investment Co., Ltd., and Guangfa Qianhe Investment Co., Ltd. have completed this round of investment in Ningkang Ruizhu with an amount totaling tens of millions of RMB.Riemann-Hypothesis Serves as Exclusive Financial Advisor for This Round of Financing. The injection of new capital will further support the development and clinical filing of REZUBIO's existing product pipeline, while also expanding its proprietary novel drug design platform to new targets.

Dr. Xiong Yusheng, Founder and CEO of REZUBIOHe stated, “We extend our heartfelt gratitude to the company’s strong and professional founding team for their sustained efforts, and to our investors for their unwavering support and trust. During the exceptional challenges of recent years, such perseverance and confidence have been particularly vital. Since its inception, our company has maintained a low profile, dedicated itself to R&D, and focused on innovation. The successful completion of this financing round fully acknowledges the development potential of REZUBIO’s technology platform, as well as its operational capabilities and team execution. At this critical juncture in China’s biopharmaceutical sector, as it transitions toward ‘innovation as core value,’ the company will continue to uphold an open and inclusive approach, launching products with genuine clinical differentiation based on unmet clinical needs. By leveraging our proprietary technology platforms, we aim to develop safe and efficient novel drugs, realizing our corporate vision of delivering medications that are ‘safe, effective, high-quality, and affordable,’ and striving to become the world’s most innovative targeted therapy enterprise.”

RHCstated: “We are delighted to lead this round of financing for REZUBIO and remain firmly confident in its sustained rapid growth in the future. We look forward to the early market launch of the company’s products, bringing benefits to patients worldwide.””

Xia Xin, Vice President of the Investment Business Department at Zhuhai Technology Venture Investment Co., Ltd.stated: “REZUBIO is a high-quality innovative pharmaceutical company based in Zhuhai. Its proprietary gut-restricted GPCR platform technology addresses the industry-wide challenge of systemic toxicity and side effects associated with systemic administration, significantly enhancing safety and druggability. The company’s founding team possesses extensive technical expertise and industry resources, along with experience in managing large-scale industrial production. We hope that REZUBIO will continue to thrive and make new contributions to Zhuhai’s big health industry cluster and innovation ecosystem.””

Mr. Ao Xiaomin, General Manager of Guangfa Qianhestated: “Leveraging extensive experience accumulated over years of drug development, the founding team of REZUBIO pioneered the development of a tissue-restricted small-molecule drug discovery platform. This highly innovative platform addresses the druggability challenges associated with many high-value but traditionally difficult-to-drug targets. REZUBIO’s gut-restricted candidate small molecules have been validated in animal studies, demonstrating improved safety profiles, and we look forward to their early entry into clinical trials. We also anticipate the expansion of this technological platform into additional therapeutic areas to benefit patients. Amid the current ‘capital winter’ facing the innovative drug industry, we hope that original technological breakthroughs like those achieved by REZUBIO will bring warmth and renewed confidence to the entire sector.””

Dr. Li Chaoxing, Chairman of Riemann-Hypothesis, as the exclusive financial advisor for this round of financingstated: “After years of turbulence and consolidation in the capital markets, China’s investment community now places significant emphasis on the core value of biopharmaceutical companies—innovation. In my view, REZUBIO is a frontrunner among today’s startup biotech firms in practicing independent innovation, while also standing out as a striking ‘outlier.’”’. Dr. Xiong Yusheng and Dr. Guan Hongping, the founders, possess extensive backgrounds in medicinal chemistry and biology, respectively, and have long led new drug R&D efforts at major international pharmaceutical companies. After establishing REZUBIO, they charted a novel course, and through years of steady and solid development, created the world’s first gut-restricted drug design platform targeting GPCR targets. In the three years since its inception, the company has advanced its R&D pipeline with remarkable efficiency, embodying a ‘small yet beautiful’’...model is impressive. These characteristics set REZUBIO apart from numerous startups. We believe that the platform’s unique technological advantages, combined with the team’s extensive R&D experience, will sustain the company’s industry competitiveness in its future development.”

RHC was established in January 2015 as one of the first private equity fund management companies in China’s insurance industry to be initiated and funded by insurance capital. After eight years of development, RHC has achieved an assets under management (AUM) scale of RMB 30 billion, with business segments covering funds of funds (FOF) and direct investments, focusing on the healthcare, emerging technology, new consumption, and real estate sectors.

Zhuhai Technology Venture Investment Co., Ltd. was officially launched in January 2016 as a state-owned comprehensive venture capital service platform established by the Zhuhai Municipal Committee of the Communist Party of China and the Zhuhai Municipal People’s Government to implement the national innovation-driven development strategy, operating under the principles of “government guidance, market-oriented operation, and corporate management.” Since its inception, Zhuhai Tech VC has adhered to its positioning in “local early- to mid-stage technology investment,” supporting Zhuhai’s sci-tech innovation industry in “optimizing existing assets and expanding new growth.” Over seven years of development, Zhuhai Tech VC has managed and leveraged over RMB 10 billion in capital, successfully nurturing Zhuhai CosMX, Actions Technology, and Gaoling Information as the first three companies from Zhuhai to list on the STAR Market, while precisely covering numerous local star sci-tech innovation projects.

Guangfa Qianhe is a wholly-owned alternative investment platform under GF Securities, currently focusing primarily on equity investments with an emphasis on advanced manufacturing, healthcare, new consumption, hard technology, and soft technology. In recent years, Guangfa Qianhe has been featured on multiple industry rankings due to its outstanding investment performance. In the healthcare sector, its representative portfolio companies include Borui Medicine (688166.SH), Sunshine Noah (688621.SH), Baiyang Pharma (301015.SZ), Dongxing Medical (301290.SZ), CytoSofia, Kelin Likang, Shandong Kanghua Bio, ImmuneOnco, Belief Therapeutics, Yinghang Bio, MaikeKang, and Sinotau Pharmaceuticals.

Riemann-Hypothesis, founded in 2018 by Dr. Li Chaoxing upon his return to China from the United States, is an integrated platform for “institutionalized” industrial innovation focused on the early-stage life sciences sector. Adhering to its original mission of collaborating with scientist-entrepreneurs who possess global vision, profound insights, and ambitious aspirations, Riemann-Hypothesis is dedicated to providing early-stage investment and “full-service” operational incubation for original and pioneering biomedical projects worldwide. It has fully established its proprietary “institutionalized” incubation system, thereby breaking through the limitations of traditional technology transfer, venture capital investment, and boutique investment banking.